Sania Therapeutics is focused on developing precision therapies aimed at treating prevalent nervous system disorders through innovative technologies. Their approach combines targeted delivery with controllable therapeutics, utilizing a "human-first" methodology that involves recreating human neural circuitry in the lab. This allows for predictable translation of therapies from research to clinical application, enhancing safety profiles and reducing development costs. Their proprietary technologies enable the engineering of cell-type specific gene delivery vectors, facilitating the efficient identification of new therapeutic options that can be effectively translated into patient care.

The company also employs a neuromodulation system that normalizes dysfunctional electrical activity in neural circuits, functioning as an adjustable 'remote control' for targeted neuronal activity. This system allows for a minimally invasive delivery method, where therapies are activated only when a patient consumes an oral medication, ensuring safety and specificity. Sania Therapeutics is advancing its pipeline with plans for clinical trials in 2026, starting with treatments for spasticity, and aims to address a range of other high unmet medical needs in the future.

United Kingdom

Built for precision, designed for patients. Sania [sah-nee-ah] is a London based biotech company building therapeutics that transform the lives of people with diseases of dysfunctional neural circuits.

Sania Therapeutics

Company Details